Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (3568)	8/9/1999 12:47:00 PM
From: M. Ramle	Read Replies (1) \| Respond to of 10280

Dave: If I remember correctly from the Los Angeles Luncheon late July, David Southwell seemed more excited and wishful that the FTC would block the Prozac deal with Lilly, because they felt that every joe schmo would be chasing after them for that deal at much better terms. Either way, D.S. felt that they have a winner drug very much in demand. Good Luck. Mazen

To: David Howe who wrote (3568)	8/9/1999 1:02:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 10280

David, FTC investigations are by their nature open-ended and slow. My guess is the FTC jumped into this one at the instigation of Barr Labs, who want to bring out a generic Prozac without excessive competition from the ICE Prozac. Given that the FTC blessed the Claritin deal, it is hard to see how they could complain about the Prozac deal. True, Prozac is perhaps higher profile, but Claritin has (as I recall) a bigger market share than Prozac. So I'm optimistic that there will be a favorable resolution. As to the SEPR stock price, people have to remember that SEPR is still very much a story stock, and as such is vulnerable to anything that clouds the story. We've had the FTC investigation, the nora/J&J fallout, no resolution yet to the Allegra patent dispute, the slowish start to Xopenex, plus some active short sellers spreading tales of woe. For the brave, who believe the long-term story is intact, I feel these are attractive prices. For the not-so-brave, it might be more prudent to wait until we get some good news or until some of these outstanding issues are resolved. Peter